| Company Name: |
NCE Biomedical Co.,Ltd. |
| Tel: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
| Email: |
|
| Company Name: |
SPIRO PHARMA |
| Tel: |
|
| Email: |
eric_feng1954@126.com |
|
| Product Name: | EC-17 | | Synonyms: | EC-17;LMEBZGHLPGBLSU-PMERELPUSA-N;L-Glutamine, N2-[4-[[(2-amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-N-[2-[[[(3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-5-yl)amino]thioxomethyl]amino]ethyl]-;EC-17 free acid;Folate-FTIC;FTIC-Folate;EC-17 (Folate-EN-FITC) | | CAS: | 583037-91-6 | | MF: | C42H36N10O10S | | MW: | 872.86 | | EINECS: | | | Product Categories: | | | Mol File: | 583037-91-6.mol |  |
| | EC-17 Chemical Properties |
| density | 1.67±0.1 g/cm3(Predicted) | | pka | 3.57±0.10(Predicted) |
| | EC-17 Usage And Synthesis |
| Uses | Folate-FITC (EC-17) is a folic acid derivative that binds to fluorescein isothiocyanate (FITC) to give it fluorescent labeling properties. Folate-fitc is used to induce the formation of pseudo-immunological synapses between anti-FITC CAR T cells and target cells expressing Folate receptors (FRα or FRβ). Folate-FITC can be used to develop controlled CAR-T cell therapies for research in non-small cell lung cancer (NSCLC)[1]. | | References | [1] Chu W, et al. Bi-specific ligand-controlled chimeric antigen receptor T-cell therapy for non-small cell lung cancer[J]. BioScience trends, 2018, 12(3): 298-308. DOI:10.5582/bst.2018.01048 |
| | EC-17 Preparation Products And Raw materials |
|